Kinsenoside alleviates oxidative stress-induced blood-brain barrier dysfunction via promoting Nrf2/HO-1 pathway in ischemic stroke

Eur J Pharmacol. 2023 Jun 15:949:175717. doi: 10.1016/j.ejphar.2023.175717. Epub 2023 Apr 11.

Abstract

An ischemic stroke usually causes blood-brain barrier (BBB) damage and excessive oxidative stress (OS) levels. Kinsenoside (KD), a major effective compound extracted in Chinese herbal medicine Anoectochilus roxburghii (Orchidaceae), has anti-OS effects. The present study focused on exploring KD's protection against OS-mediated cerebral endothelial cell damage and BBB damage within the mouse model. Intracerebroventricular administration of KD upon reperfusion after 1 h ischemia decreased infarct volumes, neurological deficit, brain edema, neuronal loss, and apoptosis 72 h post-ischemic stroke. KD improved BBB structure and function, as evidenced by a lower 18F-fluorodeoxyglucose pass rate of the BBB and upregulation of tight junction (TJ) proteins such as occludin, claudin-5, and zonula occludens-1 (ZO-1). KD protected bEnd.3 endothelial cells from oxygen and glucose deprivation/reoxygenation (OGD/R) injury in an in-vitro study. Meanwhile, OGD/R reduced transepithelial electronic resistance, whereas KD significantly increased TJ protein levels. Furthermore, based on in-vivo and in-vitro research, KD alleviated OS in endothelial cells, which is related to nuclear factor, erythroid 2 like 2 (Nrf2) nuclear translocation as well as Nrf2/haem oxygenase 1 signaling protein stimulation. Our findings demonstrated that KD might serve as a potential compound for treating ischemic stroke involving antioxidant mechanisms.

Keywords: Blood-brain barrier; Endothelial cell; Ischemic stroke; KD; Nrf2; Oxidative stress.

MeSH terms

  • Animals
  • Blood-Brain Barrier / metabolism
  • Endothelial Cells
  • Glucose / metabolism
  • Ischemic Stroke* / metabolism
  • Mice
  • NF-E2-Related Factor 2 / metabolism
  • Oxidative Stress
  • Oxygen / metabolism
  • Reperfusion Injury* / metabolism
  • Stroke* / drug therapy
  • Stroke* / metabolism
  • Tight Junction Proteins / metabolism

Substances

  • 3-glucopyranosyloxybutanolide
  • NF-E2-Related Factor 2
  • Tight Junction Proteins
  • Oxygen
  • Glucose